Page 528 - Clinical Immunology_ Principles and Practice ( PDFDrive )

508 ParT fOur Immunological Deficiencies

80. Messina C, Faraci M, de Fazio V, et al. Prevention and treatment of acute [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, Non-U.S.
GvHD. Bone Marrow Transplant [Review]. 2008;41(Suppl. 2):S65–70. Gov’t]. 2014;6(227):227ra33.
81. Somech R, Kavadas FD, Atkinson A, et al. High-dose methylprednisolone 85. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, et al. Gene therapy
is effective in the management of acute graft-versus-host disease in severe for primary immunodeficiencies: Part 1. Curr Opin Immunol
combined immune deficiency. J Allergy Clin Immunol [Letter]. [Comparative Study Research Support, Non-U.S. Gov’t Review].
2008;122(6):1215–16. 2012;24(5):580–4.
82. Fischer A, Hacein-Bey Abina S, Touzot F, et al. Gene therapy for primary 86. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in
immunodeficiencies. Clin Genet [Review]. 2015;88(6):507–15. human repopulating haematopoietic stem cells. Nature [Research
83. Hacein-Bey-Abina S, Pai SY, Gaspar HB, et al. A modified gamma- Support, Non-U.S. Gov’t]. 2014;510(7504):235–40.
retrovirus vector for X-linked severe combined immunodeficiency. N 87. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human
Engl J Med [Clinical Trial, Phase I Clinical Trial, Phase II Multicenter gene correction using designed zinc-finger nucleases. Nature
Study Research Support, N.I.H., Extramural Research Support, Non-U.S. 2005;435(7042):646–51.
Gov’t]. 2014;371(15):1407–17.
84. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-
Aldrich syndrome—long-term efficacy and genotoxicity. Sci Transl Med